Abstract Library

#3068 WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)

Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Crespo G,

Keywords: G3 NEN, epidemiology, survival, patterns of care, response to chemotherapy,

#3051 Epidemiology, Pathological and Clinical Features of 4307 Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of the Spanish Neuroendocrine Cancer Registry (R-GETNE)

Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Alonso T,

Keywords: GEP-NEN, tumor registry, survival, prognosis, epidemiology,

#3016 DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance

Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liverani C

Authors: Liverani C, Bongiovanni A, Pieri F, Foca F, Ravaioli S,

Keywords: DLL3, RB1, prognostic biomarker, GEP-NEN,

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,

#2981 The Distance from Pathology to Molecular Imaging: SSTR Expression Comparison in 100 Gastroenteropancreatic Neuroendocrine Neoplasms

Introduction: Somatostatin receptor (SSTR) overexpression is a unique feature of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which establish the basis for both diagnosis and therapy. SSTR status can be evaluated by immunohistochemical staining (IHC) and 68Ga-DOTATATE PET/CT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Yu J

Authors: Yu J, Cao F, Yang Z, Sun Y,

Keywords: GEP-NEN, SSTR, PET/CT, IHC,